| Mar-2025 | Dec-2024 | Sep-2024 | Jun-2024 | Mar-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 0% | 0% | 0% | 0% | 0% |
Indian | 52.73% | 52.73% | 54.72% | 54.72% | 54.79% |
Total Promoter | - | - | - | - | - |
Institutions | 40.97% | 40.17% | 38.2% | 37.42% | 36.72% |
Non-Institutions | 6% | 6.79% | 6.73% | 7.42% | 8.17% |
Total Non-Promoter | 46.97% | 46.97% | 44.94% | 44.84% | 44.89% |
Custodian | 0.29% | 0.29% | 0.33% | 0.42% | 0.3% |
Total | 100% | 100% | 100% | 100% | 100% |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
